Compare Equinor ASA (EQNR) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Stryker Corporation — how do they compare? Equinor ASA trades at $43.01 (market cap $101.62B), while Stryker Corporation trades at $277.33 (market cap $106.24B). The key difference: Equinor ASA and Stryker Corporation are close in size by market cap, and Equinor ASA pays the higher dividend (3.63%). Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and Stryker Corporation for 21 Days on average.
| EQNR | SYK | |
|---|---|---|
Market Cap | $101.62B | $106.24B |
Volume | 4,991,782 | 2,982,001 |
Sector | Energy | Health |
52-Week High | $45.75 | $388.35 |
52-Week Low | $22.41 | $269.75 |
Typical Hold Time | 59 Days | 21 Days |
Enterprise Value | $110.31B | $117.70B |
Dividend Yield | 3.63% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $42.93, up 3.17% today, with a bullish technical signal and strong valuation metrics including a P/E of 11.63 and EV/EBITDA of 2.39. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. The company maintains robust cash flow from operations at $20.0 billion in 2025 and has announced dividends and share buy-backs, reflecting financial health.
The outlook is positive with a consensus price target of $87.50, implying significant upside. Key opportunities include LNG expansion plans and cost efficiency, while risks involve volatile energy prices and execution challenges. Analyst sentiment is mixed but leans bullish, supported by strong institutional interest and strategic growth initiatives.
Stryker (SYK) trades at $277.33, up 0.7% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus. Recent news highlights ongoing legal scrutiny related to a manufacturing issue disclosed in September 2026, which caused an 8.8% stock drop, but the company continues to innovate with product launches like Prophecy surgical planning.
The outlook for SYK is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities include robust profitability and growth in medical technology, but risks persist from legal investigations and potential operational disruptions. Investors should weigh strong analyst support against near-term sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
